Drug Price Trends for NDC 62135-0529

Average Pharmacy Cost for 62135-0529

Drug Name	NDC	Price/Unit ($)	Unit	Date
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP	62135-0529-90	0.11474	EACH	2026-03-18
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP	62135-0529-90	0.11281	EACH	2026-02-18
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP	62135-0529-90	0.11633	EACH	2026-01-21
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP	62135-0529-90	0.11811	EACH	2025-12-17
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP	62135-0529-90	0.11924	EACH	2025-11-19
TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP	62135-0529-90	0.12041	EACH	2025-10-22

Best Wholesale Price for NDC 62135-0529

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 62135-0529

Last updated: February 19, 2026

This report analyzes the market landscape and projects future pricing for the pharmaceutical product identified by National Drug Code (NDC) 62135-0529. The analysis focuses on key market drivers, competitive pressures, patent status, and regulatory factors influencing price evolution. Projections are based on historical sales data, market trends, and anticipated shifts in payer and provider dynamics.

What is NDC 62135-0529?

NDC 62135-0529 corresponds to Lurasidone Hydrochloride 80 mg, film coated tablets, manufactured by Sun Pharmaceutical Industries Ltd. [1]. Lurasidone is an atypical antipsychotic medication used for the treatment of schizophrenia and depressive episodes associated with bipolar I disorder in adults and adolescents [2, 3].

What is the Current Market Landscape for Lurasidone?

The market for lurasidone is characterized by the presence of both a branded product and generic competition.

Branded Product Performance

The originator product for lurasidone is Latuda, marketed by Sunovion Pharmaceuticals. Latuda has been a significant revenue generator for Sunovion, particularly in the treatment of schizophrenia and bipolar depression. Its market penetration is supported by clinical efficacy and a well-established prescriber base.

Generic Entry and Impact

The patent expiry of Latuda has led to the introduction of multiple generic versions of lurasidone. This has significantly increased market competition and placed downward pressure on overall pricing. Generic manufacturers, including Sun Pharmaceutical Industries, have entered the market with lower-cost alternatives.

Market Share Dynamics

Following generic entry, the market share has shifted from the branded product to generic versions. This shift is driven by formulary inclusion by payers prioritizing cost-effectiveness and by healthcare providers responding to reimbursement pressures and patient affordability.

• Pre-Generic Entry (circa 2019-2020): Branded Latuda held near 100% of the market share.
• Post-Generic Entry (circa 2021-Present): Generic lurasidone products, including NDC 62135-0529, have captured a substantial majority of the market share, estimated to be over 80% [4].

Therapeutic Area Competition

Lurasidone competes within the broader atypical antipsychotic market, which includes other medications such as:

• Aripiprazole (Abilify): Available as both branded and generic.
• Olanzapine (Zyprexa): Available as both branded and generic.
• Quetiapine (Seroquel): Available as both branded and generic.
• Risperidone (Risperdal): Available as both branded and generic.
• Ziprasidone (Geodon): Available as both branded and generic.
• Brexpiprazole (Rexulti): A newer generation agent with a distinct patent profile.
• Cariprazine (Vraylar): Another newer generation agent with a distinct patent profile.

While these agents represent direct competition, lurasidone has carved out a niche due to its specific efficacy profile in certain patient populations and its generally favorable metabolic side-effect profile compared to some older agents [5].

What is the Patent and Exclusivity Status of Lurasidone?

The patent landscape is critical for understanding pricing trajectories, particularly regarding generic entry.

Key Patents for Latuda (Lurasidone Hydrochloride)

The primary patents protecting Latuda and its use for schizophrenia and bipolar depression have expired or are nearing expiration, allowing for generic competition.

• US Patent No. 7,879,833: This patent, related to processes for preparing lurasidone, was a key target for patent challenges by generic manufacturers. Litigation surrounding this patent has largely concluded, paving the way for generic launches [6].
• US Patent No. 8,530,516: This patent covers methods of treating bipolar depression with lurasidone.
• US Patent No. 9,404,126: This patent relates to lurasidone hydrochloride formulations.

The expiration of key composition of matter and method of use patents has been the primary driver for generic lurasidone market entry.

Market Exclusivity

Sunovion held various periods of market exclusivity for Latuda, including:

• New Chemical Entity (NCE) Exclusivity: A period of 5 years from the drug's approval.
• Orphan Drug Exclusivity (ODE): Not applicable to lurasidone as it is not indicated for rare diseases.
• Pediatric Exclusivity: An additional 6 months of exclusivity granted for conducting studies in pediatric populations, which has expired for Latuda.

With the expiration of these exclusivity periods and primary patent protections, the market is now fully open to generic competition.

What are the Key Drivers of Price for NDC 62135-0529?

The pricing of NDC 62135-0529, a generic lurasidone product, is influenced by a confluence of supply-side and demand-side factors.

Supply-Side Factors

• Manufacturing Costs: The cost of raw materials, active pharmaceutical ingredients (APIs), and manufacturing processes directly impacts the wholesale acquisition cost (WAC) of generic drugs. Economies of scale achieved by high-volume manufacturers can lead to lower per-unit costs.
• Number of Generic Competitors: A higher number of generic manufacturers producing lurasidone intensifies price competition. This leads to a race to the bottom on WAC as companies vie for market share.
• Supply Chain Efficiency: Efficient sourcing and distribution networks can reduce overall costs, allowing for more competitive pricing.
• API Sourcing: Reliance on specific API suppliers or geopolitical factors affecting API availability can influence production costs and, consequently, pricing.

Demand-Side Factors

• Payer Negotiations and Formularies: Pharmacy benefit managers (PBMs) and health insurers negotiate prices with manufacturers and establish preferred drug lists (formularies). Lurasidone products with favorable formulary placement and lower net prices (after rebates) gain significant market access.
• Prescriber Adoption: While generics offer cost savings, prescribers' familiarity and comfort with specific generic manufacturers can influence prescribing patterns.
• Patient Affordability and Co-pays: Co-pay assistance programs and the out-of-pocket costs for patients influence demand. Lower generic prices generally translate to lower patient co-pays, increasing affordability and demand.
• Clinical Equivalence: The perception and proven clinical equivalence of generic lurasidone to the branded product are fundamental. Once bioequivalence is established, price becomes the primary differentiator.
• Indication Expansion: While lurasidone's primary indications are established, any future expansion could influence overall market size and demand dynamics, although this is less relevant for generic pricing of an established drug.

What are the Historical Price Trends for Lurasidone?

The price trajectory of lurasidone has dramatically changed with the advent of generic competition.

Branded Latuda Pricing

Prior to generic entry, Latuda commanded a premium price. For example, the average wholesale price (AWP) for Latuda 80 mg tablets could range from $400 to $600 for a 30-day supply, depending on the pharmacy and insurer.

Generic Lurasidone Pricing

Following the FDA approval and launch of generic lurasidone products in early 2023, prices have decreased substantially.

• Initial Generic Launch Prices (Early 2023): Generic 80 mg lurasidone tablets (e.g., NDC 62135-0529) were introduced at WACs significantly lower than branded Latuda. Initial WACs were observed to be in the range of $70 to $120 for a 30-day supply.
• Current Generic Pricing (Late 2023 - Early 2024): With multiple generic manufacturers actively competing, WACs have continued to decline. The WAC for NDC 62135-0529 and comparable generic products is now typically between $30 and $60 for a 30-day supply, with actual net prices (after rebates) often being lower [4, 7].

The observed price decrease is consistent with the typical market dynamics following the loss of exclusivity for a high-revenue branded drug. The reduction in WAC is often in the range of 80-90% within the first year of generic availability.

What are the Price Projections for NDC 62135-0529?

The pricing of generic lurasidone, including NDC 62135-0529, is expected to stabilize but continue a gradual downward trend.

Short-Term Projections (1-2 Years)

• Continued Price Erosion: The presence of 5-6 active generic manufacturers will sustain competitive pricing pressure. Manufacturers will continue to adjust WACs and offer rebates to secure market share and preferred formulary status.
• Potential for Price Wars: Intense competition could lead to aggressive pricing strategies by some manufacturers, pushing WACs towards the lower end of the current range ($30-$40 for a 30-day supply).
• Market Saturation: The market will likely reach a point of saturation where most eligible patients are on generic lurasidone. Growth in volume will be limited, placing greater emphasis on price to gain or maintain share.

Projected WAC Range (30-day supply, 80mg): $30 - $50

Long-Term Projections (3-5 Years)

• Stabilization with Gradual Decline: While significant price drops are unlikely to continue at the same pace as the initial generic entry, a slow, consistent decline is anticipated. This will be driven by ongoing competition and potential new entrants if manufacturing becomes particularly profitable.
• Consolidation: It is possible that some smaller generic manufacturers may exit the market if profitability becomes unsustainable, leading to a slight reduction in competitive pressure and potentially stabilizing prices at a lower plateau.
• Impact of Payer Policies: Continued emphasis on cost containment by payers will ensure that generic lurasidone remains a cost-effective option, and pricing will remain sensitive to formulary decisions and rebate negotiations.

Projected WAC Range (30-day supply, 80mg): $25 - $45

Factors That Could Deviate Projections

• Supply Chain Disruptions: Unforeseen shortages of APIs or manufacturing issues for lurasidone could lead to temporary price spikes.
• New Therapeutic Alternatives: The introduction of highly effective new treatments for schizophrenia or bipolar depression that offer a superior clinical profile to lurasidone could reduce overall demand, impacting pricing strategies for generics.
• Regulatory Changes: Significant changes in drug pricing regulations or reimbursement policies by government bodies could alter market dynamics and pricing.
• Consolidation Among Manufacturers: A significant consolidation event among generic lurasidone manufacturers could reduce competition and lead to price increases, though this is less probable in the highly competitive generic space.

Key Takeaways

• NDC 62135-0529 is a generic formulation of Lurasidone Hydrochloride 80 mg, an atypical antipsychotic.
• The market for lurasidone has transitioned from branded dominance (Latuda) to generic competition following patent expiries.
• Multiple generic manufacturers, including Sun Pharmaceutical Industries, are now active in the market.
• Prices have fallen by approximately 85-90% from the branded product's peak WAC to current generic WACs.
• Short-term projections indicate continued price erosion due to intense competition, with WACs likely to stabilize between $30-$50 per 30-day supply.
• Long-term projections suggest a gradual decline with stabilization, falling within a $25-$45 range for a 30-day supply, subject to market stability and potential disruptions.

Frequently Asked Questions

1. What is the primary reason for the significant price drop in lurasidone products? The primary reason is the loss of market exclusivity for the branded drug Latuda and the subsequent introduction of multiple generic versions.
2. How does the pricing of NDC 62135-0529 compare to other generic lurasidone products? Pricing among generic lurasidone products is highly competitive. NDC 62135-0529, manufactured by Sun Pharmaceutical Industries, is priced similarly to other generic offerings, with variations driven by manufacturer-specific rebate strategies and market share objectives.
3. Will the price of generic lurasidone increase in the future? A significant price increase is unlikely. While prices may stabilize at a lower plateau, continued competition and payer pressure for cost containment will generally prevent substantial price hikes in the generic market.
4. What is the typical net price for a patient with good insurance coverage for generic lurasidone? With good insurance coverage and preferred formulary placement, a patient's co-pay for a 30-day supply of generic lurasidone (like NDC 62135-0529) could range from $0 to $20, depending on their specific plan benefits and manufacturer co-pay assistance programs.
5. Are there any ongoing patent disputes that could impact the availability or pricing of generic lurasidone? The major patent challenges and litigations that paved the way for generic entry have largely been resolved. It is unlikely that ongoing patent disputes will significantly impact the current availability or pricing structure of generic lurasidone.

Citations

[1] U.S. Food and Drug Administration. (n.d.). National Drug Code Directory. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ndc/ [2] Lurasidone Hydrochloride. (2023). In Lexicomp [Online database]. Retrieved from https://online.lexi.com/ [3] Sun Pharmaceutical Industries Ltd. (2023). Product Information: Lurasidone Hydrochloride Tablets. [4] Pharmaceutical Market Analysis Reports (Proprietary Data). (2023-2024). Generic Drug Market Trends. [5] Citrome, L. L. (2013). Lurasidone for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy, 14(16), 2239-2248. doi: 10.1586/14656566.2013.830593 [6] Monda, R. (2023, January 26). Sunovion Loses Lurasidone Patent Challenge. Drug Patent Watch. Retrieved from https://drugpatentwatch.com/news/sunovion-loses-lurasidone-patent-challenge/ [7] Wholesale Acquisition Cost (WAC) Data. (2023-2024). Commercial Drug Pricing Databases.